

# Axinn's Client Awarded Attorneys' Fees in "Exceptional" PIV Case

An abstract graphic on the right side of the page features a light blue and white grid pattern that curves and flows downwards, resembling a stylized ribbon or a modern architectural element.


NEWS | 1 MIN READ

March 28, 2019


In Axinn's latest victory for its client Alvogen, a Delaware federal district court granted in part Alvogen's motion for attorneys' fees. Alvogen's generic version of the medication Uceris<sup>®</sup> had been accused of infringing a patent owned by Cosmo Technologies Ltd. At trial, Alvogen prevailed on its motion for a judgment of noninfringement under Rule 52(c) made at the close of Plaintiffs' case-in-chief, which was "a truly rare occurrence (and nearly-unprecedented for the undersigned Judge)." The Federal Circuit summarily affirmed the district court's decision on January 14, 2019. On March 27, 2019, the district court found this case was "exceptional" under 35 U.S.C. § 285 and awarded Alvogen its attorneys' fees incurred after the pretrial conference. The district court based its decision on "the substantive weakness of Plaintiffs' claims of infringement" and Plaintiffs' "unreasonable" and prejudicial litigation conduct, including their "last-minute without-warning decision" to drop two other patents just two business days before trial. The Axinn team included Matt Becker and Jason Murata.

## Related People

---



Matthew J. Becker



Jason Murata

## Related Services

---

Intellectual Property

To subscribe to our publications, [click here](#).

## Featured Insights

- American Bar Association 2025 Asia-Pacific Conference  
**SPEAKING ENGAGEMENT    ANTITRUST**
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference  
**SPONSORSHIP    ANTITRUST**
- GCR Live: Law Leaders Global 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- The 32nd Annual Marketing Partner Forum  
**EVENT**
- SABA North America Corporate Counsel Retreat 2025  
**SPONSORSHIP    ANTITRUST**
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025  
**CLIENT ALERTS    ANTITRUST**

- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards

**AWARDS & RECOGNITIONS     ANTITRUST**

- Merger Remedies Back in Vogue Under Trump

**MEDIA MENTIONS     ANTITRUST**

- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

**AXINN VIEWPOINTS     INTELLECTUAL PROPERTY**

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

**AXINN VIEWPOINTS     INTELLECTUAL PROPERTY**